Most severe obesity still goes untreated as GLP-1 use climbs and surgery slips

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially—from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025—according to a new real-world analysis presented at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery (ASMBS2026).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup